Voya Investment Management LLC Sells 258,200 Shares of Haemonetics Corporation $HAE

Voya Investment Management LLC reduced its stake in shares of Haemonetics Corporation (NYSE:HAE) by 81.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 58,752 shares of the medical instruments supplier’s stock after selling 258,200 shares during the period. Voya Investment Management LLC owned about 0.12% of Haemonetics worth $3,734,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. Quarry LP grew its holdings in Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares during the period. University of Texas Texas AM Investment Management Co. bought a new position in shares of Haemonetics during the 1st quarter worth $65,000. Strs Ohio purchased a new stake in Haemonetics in the 1st quarter worth about $140,000. KBC Group NV raised its stake in Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock valued at $154,000 after acquiring an additional 401 shares during the period. Finally, AlphaQuest LLC lifted its holdings in Haemonetics by 71.5% during the first quarter. AlphaQuest LLC now owns 3,140 shares of the medical instruments supplier’s stock valued at $200,000 after purchasing an additional 1,309 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 1.2%

Haemonetics stock opened at $50.54 on Friday. The business’s fifty day moving average is $61.19 and its 200 day moving average is $64.88. Haemonetics Corporation has a one year low of $49.43 and a one year high of $94.99. The stock has a market capitalization of $2.43 billion, a PE ratio of 15.45, a price-to-earnings-growth ratio of 0.94 and a beta of 0.39. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company had revenue of $321.39 million during the quarter, compared to analysts’ expectations of $305.12 million. During the same quarter in the prior year, the business earned $1.02 earnings per share. Haemonetics’s revenue for the quarter was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, sell-side analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on HAE shares. Mizuho reduced their target price on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $62.00 price objective (down from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Raymond James Financial cut shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and lowered their target price for the company from $105.00 to $78.00 in a report on Monday, August 11th. Barrington Research cut their price target on Haemonetics from $95.00 to $86.00 and set an “outperform” rating for the company in a report on Friday, August 8th. Finally, Robert W. Baird began coverage on Haemonetics in a research report on Thursday, June 26th. They issued an “outperform” rating and a $87.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average price target of $78.78.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.